About GHK-Cu Store

What this site is

GHK-Cu Store is an independent editorial project that publishes summaries of the peer-reviewed research literature on GHK-Cu. We are not a clinic. We do not employ clinicians and we do not provide medical advice. We do not manufacture, sell, or distribute any product. Our work is editorial commentary on publicly available science.

The name carries the word "store," and the design leans into the inversion deliberately: this is a store of evidence, not of product — a statement of what the copper-tripeptide research establishes and what it has not, read the way a banking app reads a balance. There is no checkout here, no price, no order form, and no vendor relationship. Where you see a figure, you see its source posted beside it.

Every quantitative claim on this site resolves to a numbered citation on the GHK-Cu references and citations page. We lead with what each study measured and we are explicit about which tier of evidence each figure sits in — the controlled human data, the in-vitro dose-response, the rodent behavioral work, and the gaps the literature has not yet filled.

How we read the evidence

The GHK-Cu literature has an unusual shape: a strong, decades-deep in-vitro and topical-cosmetic record, a single 45-patient controlled hair trial of a combination formulation, and a hard gap where validated human pharmacokinetic data should be ^[4][6]. A large share of the foundational mechanistic and review literature comes from one investigator group, which is itself a fact we post rather than smooth over ^[2][6].

That is why this digest uses a statement metaphor. Confirmed findings — the picomolar collagen dose-response ^[1], the 70%/50%/40% procollagen comparison ^[3], the +71.5 versus +9.6 hair-count delta ^[4] — are posted as green-status lines. The honest gaps — no validated human PK, the single-source caveat, the AHK-Cu-is-an-analog-not-GHK-Cu note — are posted as amber-status lines ^[6][12]. Both belong on the statement.

The domain modifier "store" is editorial framing — a position this publisher occupies relative to the literature, a curator of figures — not a claim that the site sells, dispenses, or stocks anything. We hold no inventory and take no orders.

Copper peptide side effects and tolerability in the literature

What are the downsides of copper peptides?

Reported concerns include low native topical bioavailability, localized hyperpigmentation in some applications, vitamin-C/low-pH incompatibility, a theoretical copper-accumulation risk with prolonged systemic use, and an evidence base that is largely in-vitro or rodent ^[6][14]. Localized hyperpigmentation has been reported in some topical copper-peptide applications, and a vitamin-C or low-pH formulation can destroy both actives through copper reduction or competition ^[6][14].

Is copper peptide safe: what the studies show

Topical Copper Tripeptide-1 carries a long cosmetic safety record, and the GHK-Cu complex's high copper-stability constant (log K ~16.4) limits pro-oxidant free-copper release ^[6]. The unresolved part is systemic: no validated human pharmacokinetic or long-term systemic-safety data exist for injectable or oral GHK-Cu, so systemic safety remains uncharacterized rather than established ^[6].

Is GHK-Cu safe for long-term use?

Topical Copper Tripeptide-1 has a long cosmetic safety record, but no validated human pharmacokinetic or long-term systemic-safety data exist; the high copper-stability constant limits free-copper release, while copper-accumulation risk with prolonged systemic use remains theoretical ^[6]. Rodent studies used copper loads below the ion-toxicity threshold, and no human copper-toxicity case attributed to GHK-Cu appears in the peer-reviewed record ^[6].

What shouldn't be mixed with GHK-Cu?

Strong reducing agents such as ascorbic acid below about pH 3.5 reduce Cu(II) and break the complex, and AHAs/BHAs and other low-pH actives can destabilize it or compete for copper; the complex is most stable near pH 5-6.5 ^[6][14].

Regulatory status

GHK-Cu has no FDA- or EMA-approved therapeutic indication by any route. Topical Copper Tripeptide-1 is a legal cosmetic ingredient with a long market history; injectable, oral or other systemic use is unapproved and research-only ^[6]. This site describes research findings only and uses "studied at X in [species or model]" framing throughout — it does not provide dosing guidance for people.

The distinction between the topical cosmetic record and the systemic research-only status runs through everything here. A reader should treat the topical-dermatologic figures as a mature, market-backed record and the systemic and injectable figures as early-stage research with no validated human pharmacokinetic foundation ^[6].